FERMT2 and cholangiocarcinoma: Previous studies showed that FERMT2 highly expressed in NSCLC, esophageal squamous cancer, breast cancer, cholangiocarcinoma and pancreatic cancer, and can affect the migration ability of tumor cells and disease progression [47–49].